S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
NASDAQ:FLXN

Flexion Therapeutics Stock Forecast, Price & News

$9.31
-0.13 (-1.38 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.26
$9.44
50-Day Range
$4.40
$9.44
52-Week Range
$4.30
$13.66
Volume1.83 million shs
Average Volume1.10 million shs
Market Capitalization$468.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
30 days | 90 days | 365 days | Advanced Chart
Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Flexion Therapeutics logo

About Flexion Therapeutics

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLXN
Employees
257
Year Founded
N/A

Sales & Book Value

Annual Sales
$85.55 million
Book Value
($0.34) per share

Profitability

Net Income
$-113.71 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$468.22 million
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

156th out of 1,361 stocks

Pharmaceutical Preparations Industry

66th out of 668 stocks

Analyst Opinion: 4.2Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

Is Flexion Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Flexion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLXN, but not buy additional shares or sell existing shares.
View analyst ratings for Flexion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Flexion Therapeutics?

Wall Street analysts have given Flexion Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Flexion Therapeutics?

Flexion Therapeutics saw a decrease in short interest in September. As of September 30th, there was short interest totaling 3,510,000 shares, a decrease of 38.1% from the September 15th total of 5,670,000 shares. Based on an average daily trading volume, of 1,600,000 shares, the days-to-cover ratio is presently 2.2 days. Currently, 8.4% of the company's shares are sold short.
View Flexion Therapeutics' Short Interest
.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Flexion Therapeutics
.

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced its quarterly earnings results on Wednesday, August, 4th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.06. The specialty pharmaceutical company had revenue of $28.18 million for the quarter, compared to the consensus estimate of $28.02 million.
View Flexion Therapeutics' earnings history
.

How has Flexion Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLXN shares have decreased by 24.4% and is now trading at $9.31.
View which stocks have been most impacted by COVID-19
.

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $120 million-$130 million, compared to the consensus revenue estimate of $133.34 million.

What price target have analysts set for FLXN?

8 brokerages have issued 1-year price targets for Flexion Therapeutics' stock. Their forecasts range from $6.00 to $18.00. On average, they expect Flexion Therapeutics' share price to reach $12.83 in the next year. This suggests a possible upside of 37.8% from the stock's current price.
View analysts' price targets for Flexion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Michael D. Clayman, President, Chief Executive Officer & Director
  • Fred Driscoll, Chief Financial Officer
  • William T. Andrews, Chief Medical Officer
  • Carolyn Beaty Scimemi, Chief Compliance Officer & Head-Legal Affairs
  • Christina Willwerth, Chief Strategy Officer (LinkedIn Profile)

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among Flexion Therapeutics' employees.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $9.31.

How much money does Flexion Therapeutics make?

Flexion Therapeutics has a market capitalization of $468.22 million and generates $85.55 million in revenue each year. The specialty pharmaceutical company earns $-113.71 million in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Flexion Therapeutics have?

Flexion Therapeutics employs 257 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

Where are Flexion Therapeutics' headquarters?

Flexion Therapeutics is headquartered at 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at (781) 305-7777 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.